Illumina Inc. Blows Past Guidance in Second Quarter With Strong NovaSeq Demand
Illumina Inc. (NASDAQ: ILMN) started out 2017 on a positive note by beating its first-quarter revenue guidance and coming in at the upper end of its earnings guidance. However, there were a few negatives in those results, including lower gross profit.
The gene-sequencing company announced its second-quarter results after the market closed on Tuesday. There were even more positives this time around. Here are the highlights from Illumina's quarterly update.
Image source: Getty Images.
Source: Fool.com
Illumina Inc. Stock
€120.86
1.820%
The stock is one of the favorites of our community with 33 Buy predictions and 4 Sell predictions.
As a result the target price of 161 € shows a positive potential of 33.21% compared to the current price of 120.86 € for Illumina Inc..
